Company intelligence / Profile preview

Oxford Immunotec

Abingdon, Oxfordshire, United Kingdomoxfordimmunotec.com ↗

Ownership: Private
Employees: ~275
Development stage: Commercial

Overview

The company’s lead product, the T-SPOT.TB test, has been approved in over 50 countries and used in more than 20 million tests globally. It provides a highly sensitive and specific method for diagnosing latent and active tuberculosis by measuring interferon-gamma release from antigen-specific T cells. Clinical results have demonstrated its ability to detect infections missed by traditional skin testing methods.

Therapeutic areas: Infectious Diseases
Modalities: Device (diagnostic test)Assay (ELISPOT-based T cell measurement)In vitro diagnostic test
Industry: Protein Biomarker Diagnostics

Drug pipeline

3 assets

T-SPOT.TB

Commercial

Indications: Tuberculosis

2 more assets in the full pipeline.

Request access →

Partnerships

Not explicitly listed; global distribution partners likely due to >50 country approvals.

Beyond the preview

Go deeper on Oxford Immunotec.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oxford Immunotec.

Explore the full profile